Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-pNK Cells for CD7+ Leukemia and Lymphoma
NCT02742727Phase 2Unknown
- Sponsor
- PersonGen BioTherapeutics
- Start
- Mar 2016
- Primary completion
- Mar 2017
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Anti-CD7 CAR-pNK cells in acute myeloid leukemia (AML), precursor T-cell acute lymphoblastic leukemia (T-ALL), T-cell prolymphocytic leukemia (T-PLL) and 6 more, sponsored by PersonGen BioTherapeutics. Primary endpoint: Adverse events attributed to the administration of the anti-CD7 CAR-pNK cells at 2 years. Status: unknown.
02
Drugs
Anti-CD7 CAR-pNK cells
03
Conditions
acute myeloid leukemia (AML)precursor T-cell acute lymphoblastic leukemia (T-ALL)T-cell prolymphocytic leukemia (T-PLL)T-cell large granular lymphocytic leukemia (T-LGLL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT02742727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02742727.